Merck has the first option to negotiate an exclusive license. These preclinical proof-of-principle studies will be conducted using an undisclosed Merck vaccine. Stanley Erck, president and CEO of
This independent, investigator-initiated study is being sponsored by Tatsuro Kamakura, chief medical officer of Cosmetic Surgery Seishin, in Japan. Results of the study will be available following a
PVI is a dynamic new indicator of fluid responsiveness that does not require an invasive procedure or manual calculation, yet has been demonstrated to be sensitive to changes
The recombinant adenovirus serotype 26 (rAd26) vector is specifically designed to avoid the pre-existing immunity to the more commonly used adenovirus serotype 5 (Ad5), which has recently shown
These contracts with a pharmaceutical company (the sponsor) are part of a series of seven contracts related to clinical trials that form part of a global development program
Results from this 28 week randomized, double-blind, placebo-controlled, multi-center pivotal study will be presented during the fourth quarter of 2008 and be used to file for licensure in
Asuragen is transferring its microRNA’s (miRNA) therapeutic intellectual property to Mirna Therapeutics and seeding the new company with $3 million in capital. miRNAs are naturally occurring small RNAs
Under the terms of the agreement, Akorn will be responsible for development, marketing and distribution of the premix product. Fresenius Kabi will manufacture the product at its intravenous
The Phase II part commences after the completion of Phase I, which demonstrated a good safety profile, as well as clinical activity. The Phase II part will evaluate
Under the terms of the agreement, the companies will collaborate in adapting the Corgenix AspirinWorks test to a format compatible with automated chemistry analyzers. The AspirinWorks test will
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.